Chemical Compound Review:
Zinecard 4-[(2S)-1-(3,5- dioxopiperazin-1-yl)propan...
Synonyms:
Tepirone, Cardioxane, Dexrazoxane, ICRF-187, ADR-529, ...
Hasinoff,
Abram,
Barnabé,
Khélifa,
Allan,
Yalowich,
Iarussi,
Indolfi,
Casale,
Coppolino,
Tedesco,
Di Tullio,
Lipshultz,
Moghrabi,
Levy,
Asselin,
Barr,
Clavell,
Hurwitz,
Samson,
Schorin,
Dalton,
Lipshultz,
Neuberg,
Gelber,
Cohen,
Sallan,
Silverman,
Sparano,
Speyer,
Gradishar,
Liebes,
Sridhara,
Mendoza,
Fry,
Egorin,
Hoekman,
van der Vijgh,
Vermorken,
Hofland,
Thougaard,
Dejligbjerg,
Jensen,
Kristjansen,
Rengtved,
Sehested,
Jensen,
- Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. Hochster, H., Liebes, L., Wadler, S., Oratz, R., Wernz, J.C., Meyers, M., Green, M., Blum, R.H., Speyer, J.L. J. Natl. Cancer Inst. (1992)
- Anthracycline-induced cardiotoxicity. Shan, K., Lincoff, A.M., Young, J.B. Ann. Intern. Med. (1996)
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Moghrabi, A., Levy, D.E., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Samson, Y., Schorin, M., Dalton, V.K., Lipshultz, S.E., Neuberg, D.S., Gelber, R.D., Cohen, H.J., Sallan, S.E., Silverman, L.B. Blood (2007)
- Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia. Lemez, P. J. Clin. Oncol. (1997)
- Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Sawyer, D.B., Fukazawa, R., Arstall, M.A., Kelly, R.A. Circ. Res. (1999)
- Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. Basser, R.L., Sobol, M.M., Duggan, G., Cebon, J., Rosenthal, M.A., Mihaly, G., Green, M.D. J. Clin. Oncol. (1994)
- Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Bernitsas, E., Wei, W., Mikol, D.D. Ann. Neurol. (2006)
- Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Hoekman, K., van der Vijgh, W.J., Vermorken, J.B. Drugs (1999)
- Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. Cvetković, R.S., Scott, L.J. Drugs (2005)
- The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Hasinoff, B.B., Abram, M.E., Barnabé, N., Khélifa, T., Allan, W.P., Yalowich, J.C. Mol. Pharmacol. (2001)
- Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin. Styczynski, J., Wysocki, M., Balwierz, W., Kowalczyk, J.R. Leukemia (2002)
- Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Hasinoff, B.B., Creighton, A.M., Kozlowska, H., Thampatty, P., Allan, W.P., Yalowich, J.C. Mol. Pharmacol. (1997)
- In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? Budman, D.R., Calabro, A., Kreis, W. Leukemia (2001)
- Strategies for reduction of anthracycline cardiac toxicity. Speyer, J., Wasserheit, C. Semin. Oncol. (1998)
- Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ADR-529) on iron-catalyzed lipid peroxidation. Ryan, T.P., Samokyszyn, V.M., Dellis, S., Aust, S.D. Chem. Res. Toxicol. (1990)
- American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Hensley, M.L., Schuchter, L.M., Lindley, C., Meropol, N.J., Cohen, G.I., Broder, G., Gradishar, W.J., Green, D.M., Langdon, R.J., Mitchell, R.B., Negrin, R., Szatrowski, T.P., Thigpen, J.T., Von Hoff, D., Wasserman, T.H., Winer, E.P., Pfister, D.G. J. Clin. Oncol. (1999)
- In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex. Sobol, M.M., Amiet, R.G., Green, M.D. Mol. Pharmacol. (1992)
- Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Barnabé, N., Zastre, J.A., Venkataram, S., Hasinoff, B.B. Free Radic. Biol. Med. (2002)
- Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Malisza, K.L., Hasinoff, B.B. Free Radic. Biol. Med. (1996)
- CD95/Apo-1/Fas: independent cell death induced by doxorubicin in normal cultured cardiomyocytes. Jeremias, I., Stahnke, K., Debatin, K.M. Cancer Immunol. Immunother. (2005)
- Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice. Saadane, N., Yue, P., Alpert, L., Mitmaker, B., Kirby, G.M., Chalifour, L.E. Can. J. Physiol. Pharmacol. (2001)
- Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. Sparano, J.A., Speyer, J., Gradishar, W.J., Liebes, L., Sridhara, R., Mendoza, S., Fry, D., Egorin, M.J. J. Clin. Oncol. (1999)
- Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Hofland, K.F., Thougaard, A.V., Dejligbjerg, M., Jensen, L.H., Kristjansen, P.E., Rengtved, P., Sehested, M., Jensen, P.B. Clin. Cancer Res. (2005)
- Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Links, M., Lewis, C. Drugs (1999)
- Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. Hellmann, K. J. Clin. Oncol. (2000)
- Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Iarussi, D., Indolfi, P., Casale, F., Coppolino, P., Tedesco, M.A., Di Tullio, M.T. Current medicinal chemistry. (2001)
- Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Tetef, M.L., Synold, T.W., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, G., Yen, Y., Groshen, S., Johnson, K., Lenz, H.J., Gandara, D., Doroshow, J.H. Clin. Cancer Res. (2001)
- Clinical pharmacology of dexrazoxane. Hochster, H.S. Semin. Oncol. (1998)
- Exposure to anthracyclines during childhood causes cardiac injury. Lipshultz, S.E. Semin. Oncol. (2006)